GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (STU:4QG) » Definitions » Equity-to-Asset

PCI Biotech Holding ASA (STU:4QG) Equity-to-Asset : 0.89 (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is PCI Biotech Holding ASA Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PCI Biotech Holding ASA's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €4.01 Mil. PCI Biotech Holding ASA's Total Assets for the quarter that ended in Jun. 2023 was €4.49 Mil.

The historical rank and industry rank for PCI Biotech Holding ASA's Equity-to-Asset or its related term are showing as below:

STU:4QG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45   Med: 0.86   Max: 0.95
Current: 0.89

During the past 13 years, the highest Equity to Asset Ratio of PCI Biotech Holding ASA was 0.95. The lowest was 0.45. And the median was 0.86.

STU:4QG's Equity-to-Asset is ranked better than
83.47% of 1561 companies
in the Biotechnology industry
Industry Median: 0.67 vs STU:4QG: 0.89

PCI Biotech Holding ASA Equity-to-Asset Historical Data

The historical data trend for PCI Biotech Holding ASA's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Equity-to-Asset Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 0.91 0.84 0.90 0.89

PCI Biotech Holding ASA Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.90 0.91 0.89 0.89

Competitive Comparison of PCI Biotech Holding ASA's Equity-to-Asset

For the Biotechnology subindustry, PCI Biotech Holding ASA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Equity-to-Asset falls into.



PCI Biotech Holding ASA Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

PCI Biotech Holding ASA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3.394/3.829
=

PCI Biotech Holding ASA's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=4.01/4.49
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA  (STU:4QG) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


PCI Biotech Holding ASA Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA (STU:4QG) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (STU:4QG) Headlines

No Headlines